Smoking cessation
Etiology of smoking
Tobacco smoking as self-medication
Treatment
Counseling
Recording smoking status as a vital sign increases the frequency of brief advice to patients by physicians.[1]
Demonstration of damage to lungs
In general, informing patients of their lung function as measured by spirometry does not increase smoking cession according to a systematic review by the U.S. Preventive Services Task Force (USPSTF).[2] However, in a more recent randomized controlled trial, patients in the group who were informed of their 'lung age' were more likely to stop smoking.[3] However, in this trial, "People with worse spirometric lung age were no more likely to have quit than those with normal lung age in either group".[3]
Medications
Bupropion
Bupropion is both an adrenergic uptake inhibitor and a dopamine uptake inhibitor and can help smoking cessation[4], including adding to the effective of nicotine replacement.[5]
Varenicline
Varenicline, a partial agonist at the α4β2 nicotinic acetylcholine receptor, may be more effective than bupropion[6][7]; however, bupropion is a generic drug. Varenicline is probably better than the nicotine patch; however, the only study was not blinded and was industry sponsored.[8]
The Food and Drug Administration of the United States has issued an advisory for varenicline and psychiatric disease.[9]
| Eisenberg[10] (odds ratio) |
Cochrane[11] (relative risk ratio) | |
|---|---|---|
| Bupropion | 2.07 | 1.17 |
| Varenicline | 2.41 | 1.18 |
Nicotine replacement
A systematic reviews of selected medications including nicotine replacement found that the odds ratios for quitting with nicotine are:[10]
- Spray, 2.37
- Inhaler, 2.18
- Patch, 1.88
- Gum, 1.65
Rimonabant
Rimonabant, a selective type 1 cannabinoid (CB1) receptor antagonist, improves smoking cessation and moderate weight gain associated with smoking cessation according to a meta-analysis of randomized controlled trials by the Cochrane Collaboration.[12] However, "there is current concern (August 2007) over rates of depression and suicidal thoughts in people taking rimonabant for weight control."[12]
Atomoxetine
Addiction is reinforced by the fear of experiencing the adverse effects associated with the cessation of the drug. Smoking withdrawal causes cognitive deficits analogous to attention deficit hyperactivity disorder, an observation which prompted researchers to test the hypothesis that drugs that ameliorate ADHD facilitate smoking cessation. In confirmation of this hypothesis, it was shown that atomoxetine, a norepinephrine reuptake inhibitor that is approved by the FDA to treat the symptoms of ADHD, dose-dependently reversed congnitive deficits in an animal model of nicotine withdrawal.[13] Atomoxetine is not indicated at this time as a medication to treat the ADHD-like symptoms of smoking cessation.
Combinations of medications
| Study | Subjects | Intervention | Comparison | Outcome | Results | |
|---|---|---|---|---|---|---|
| Intervention group | Comparison group | |||||
| Steinberg[14] 2009 |
Community volunteers with predefined medical illnesses | Triple therapy of nicotine patch, nicotine oral inhaler, and bupropion ad libitum | Nicotine patch alone | Abstinence at 26 weeks by 7 days exhaled carbon monoxide testing | 35% | 19% |
| Jorenby[5] 1999 |
Community volunteers without medical illness | Double therapy with bupropion and nicotine patch | Nicotine patch alone | Abstinence at 52 weeks by single exhaled carbon monoxide testing | Both drugs 36% Bupropion alone 30% |
16% |
Incentives
Financial incentives to either smokers or their health care providers may increase rates of smoking cessation.[15][16]
References
- ↑ Rothemich SF, Woolf SH, Johnson RE, et al (2008). "Effect on cessation counseling of documenting smoking status as a routine vital sign: an ACORN study". Ann Fam Med 6 (1): 60-8. DOI:10.1370/afm.750. PMID 18195316. Research Blogging.
- ↑ Lin K, Watkins B, Johnson T, Rodriguez JA, Barton MB (2008). "Screening for Chronic Obstructive Pulmonary Disease Using Spirometry: Summary of the Evidence for the U.S. Preventive Services Task Force". Ann. Intern. Med.. PMID 18316746. [e]
- ↑ 3.0 3.1 Parkes G, Greenhalgh T, Griffin M, Dent R (2008). "Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial". BMJ. DOI:10.1136/bmj.39503.582396.25. PMID 18326503. Research Blogging.
- ↑ Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC et al. (1997). "A comparison of sustained-release bupropion and placebo for smoking cessation.". N Engl J Med 337 (17): 1195-202. PMID 9337378.
- ↑ 5.0 5.1 5.2 Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR et al. (1999). "A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.". N Engl J Med 340 (9): 685-91. PMID 10053177.
Cite error: Invalid
<ref>tag; name "pmid10053177" defined multiple times with different content - ↑ Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE et al. (2006). "Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.". JAMA 296 (1): 56-63. DOI:10.1001/jama.296.1.56. PMID 16820547. Research Blogging.
- ↑ Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB et al. (2006). "Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.". JAMA 296 (1): 47-55. DOI:10.1001/jama.296.1.47. PMID 16820546. Research Blogging.
- ↑ Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB, Gong J et al. (2008). "Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial.". Thorax 63 (8): 717-24. DOI:10.1136/thx.2007.090647. PMID 18263663. PMC PMC2569194. Research Blogging.
- ↑ Anonymous (2009). Important Information on Chantix (varenicline) Food and Drug Administration
- ↑ 10.0 10.1 10.2 Eisenberg MJ, Filion KB, Yavin D, et al. (July 2008). "Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials". CMAJ 179 (2): 135–44. DOI:10.1503/cmaj.070256. PMID 18625984. PMC 2443223. Research Blogging.
Cite error: Invalid
<ref>tag; name "pmid18625984" defined multiple times with different content - ↑ 11.0 11.1 Hajek P, Stead LF, West R, Jarvis M, Lancaster T (2009). "Relapse prevention interventions for smoking cessation". Cochrane Database Syst Rev (1): CD003999. DOI:10.1002/14651858.CD003999.pub3. PMID 19160228. Research Blogging.
- ↑ 12.0 12.1 Cahill K, Ussher M (2007). "Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation". Cochrane Database Syst Rev (4): CD005353. DOI:10.1002/14651858.CD005353.pub3. PMID 17943852. Research Blogging.
- ↑ Davis JA, Gould TJ (September 2007). "Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning". Neuropsychopharmacology 32 (9): 2011–9. DOI:10.1038/sj.npp.1301315. PMID 17228337. Research Blogging.
- ↑ 14.0 14.1 Steinberg MB, Greenhaus S, Schmelzer AC, et al (April 2009). "Triple-combination pharmacotherapy for medically ill smokers: a randomized trial". Ann. Intern. Med. 150 (7): 447–54. PMID 19349630. [e]
- ↑ Volpp KG, Troxel AB, Pauly MV, et al (February 2009). "A randomized, controlled trial of financial incentives for smoking cessation". N. Engl. J. Med. 360 (7): 699–709. DOI:10.1056/NEJMsa0806819. PMID 19213683. Research Blogging.
- ↑ Reda AA, Kaper J, Fikrelter H, Severens JL, van Schayck CP (2009). "Healthcare financing systems for increasing the use of tobacco dependence treatment". Cochrane Database Syst Rev (2): CD004305. DOI:10.1002/14651858.CD004305.pub3. PMID 19370599. Research Blogging.